Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges? by Marcin Cieślak, Marta Słowianek

Subjects: Get full text

PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA by Jérémy eThalgott, Damien eDos-Santos-Luis, Franck eLebrin

Subjects: “…Thalidomide…”
Get full text

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13 by K. Groen, M. R. Seefat, B. van der Holt, F. H. Schjesvold, C. A. Stege, M.-D. Levin, M. Hansson, R. B. Leys, J. Regelink, A. Waage, D. Szatkowski, P. Axelsson, T. H. Do, A. Svirskaite, E. van der Spek, E. Haukas, D. Knut-Bojanowska, P. F. Ypma, C. Blimark, U.-H. Mellqvist, N. W. van de Donk, P. Sonneveld, A. Klostergaard, A. J. Vangsted, N. Abdilgaard, S. Zweegman

Get full text

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders by Katherine O. Kopp, Margaret E. Greer, Elliot J. Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H. Greig

Subjects: Get full text

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients by Joanna Barankiewicz, Anna Szumera-Ciećkiewicz, Aleksander Salomon-Perzyński, Paulina Wieszczy, Agata Malenda, Filip Garbicz, Monika Prochorec-Sobieszek, Irena Misiewicz-Krzemińska, Przemysław Juszczyński, Ewa Lech-Marańda

Subjects: Get full text

Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and literature review by Hua Huang, Shen-Xian Qian

Subjects: Get full text

Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflamma... by Tweedie David, Ferguson Ryan A, Fishman Kelly, Frankola Kathryn A, Van Praag Henriette, Holloway Harold W, Luo Weiming, Li Yazhou, Caracciolo Luca, Russo Isabella, Barlati Sergio, Ray Balmiki, Lahiri Debomoy K, Bosetti Francesca, Greig Nigel H, Rosi Susanna

Subjects: Get full text

Unrealized potential of drug repositioning in Europe during COVID-19 and beyond: a physician’s perspective by A. B. Bayoumy, N. K. H. de Boer, A. R. Ansari, F. Crouwel, C. J. J. Mulder

Subjects: Get full text

HOW PUBLIC POLICIES HAVE IMPROVED THE OVERALL SURVIVAL OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IN THE CHILEAN PUBLIC HEALTH SYSTEM by E Galindo, P Graffigna, M Russo, X Valladares, C Gajardo, D Zambrano, V Lizama, M Roa, K Lopez, G Espinoza, C Pena

“…At P2, 71% were treated with a thalidomide-based regimen (13% CTD, 87% thalidomide - dexamethasone), 20% melphalan-based regimen, and 2% bortezomib-based regimen. 21% had ASCT performed and 9% received maintenance (thalidomide-based). …”
Get full text

Why poison your baby? by Abd Razak, Dzulkifli

“…Thalidomide was later classified as a teratogen and was eventually banned. …”
Get full text

Epigenetic modulations on the fetal hemoglobin induction by Najmaldin Saki, Mehrdad Noruzinia, Saeid Kaviani, Ali Dehghani Fard, Esmaeil Mortaz

“…We showed that Thalidomide much effective in suppresseion of H3K27 methylation in comparison with Sodium butyrate. …”
Get full text

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma by Grzegorz Charliński, David H. Vesole, Artur Jurczyszyn

“…The first IMiD introduced to treat MM was thalidomide. The side effects observed during treatment with thalidomide initiated work on the synthesis of IMiD analogs. …”
Get full text

Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos by Kamm, Roger D.

“…However, current anti-angiogenic drugs such as Thalidomide still have detrimental teratogenic effects. …”
Get full text

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury by Shih Chang Hsueh, Michael T. Scerba, David Tweedie, Daniela Lecca, Dong Seok Kim, Abdul Mannan Baig, Yu Kyung Kim, Inho Hwang, Sun Kim, Warren R. Selman, Barry J. Hoffer, Nigel H. Greig

“…We developed F-3,6′-dithiopomalidomide (F-3,6′-DP) as a novel thalidomide-like compound to ameliorate inflammation. …”
Get full text

Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins by Shang-shang Wang, Qin-yi Chen, Lei-hong Xiang

“…High-dose intravenous immunoglobulin (IVIG), used either alone or in conjunction with systemic steroids and/or thalidomide, has been suggested as a first-line treatment. …”
Get full text

Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. by Travis, S, Czajkowski, M, McGovern, D, Watson, R, Bell, A

“…Treatment with prednisolone, methyl prednisolone, and thalidomide in one and prednisolone, colchicine, and cyclosporin in the other was ineffective. …”

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system by Tingting Jiang, Hui Su, Yanping Li, Yuanlin Wu, Yue Ming, Chen Li, Ruoqiu Fu, Lu Feng, Ziwei Li, Li Li, Rui Ni, Yao Liu

“…When all three algorithms showed an association between the target drug and the AE, a positive signal was generated.Results: We extracted 9,968 thalidomide, 231,926 lenalidomide, and 55,066 pomalidomide AE reports. …”
Get full text

Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum by Gustavo U. Machado, Thiago Amparo, Flávia Bulhões, Paulo R. L. Machado, Paulo R. L. Machado

“…All subjects had been on prednisone and thalidomide therapy for at least 30 months but showed inflammatory activity when doses were reduced. …”
Get full text

Maintenance therapy in multiple myeloma by Jean-Luc Harousseau

“…A number of randomized studies show a benefit from maintenance therapy with novel agents (until now, mostly thalidomide), at least in terms of response rate and progression-free survival (PFS). …”
Get full text

Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test by Lijie Xing, Hui Wang, Dan Liu, Qiang He, Zengjun Li

“…The primary tumor cells showed moderate sensitivity to bortezomib, thalidomide, and gemcitabine as a single agent and bortezomib, thalidomide, and dexamethasone (VTD) as a combined regimen. …”
Get full text